US › Healthcare

Mink Therapeutics Inc (INKT)

US · Healthcare · Biotechnology

$11.07+3.55%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-2.7M
Profit YoY
+0.9%
EPS
$-0.57
EPS estimate
$-0.77

EPS came in at -0.57 against a street estimate of -0.77 — a beat of 26.0%.

Key statistics

Market cap
$52.3M
Forward P/E
0.0
P/B
11.33
Book value
$-2.55
EPS (TTM)
$-2.80
52-week high
$18.17
52-week low
$8.48
50-day MA
$11.41
200-day MA
$11.68
Beta
0.47

Analyst view

Analysts rate Mink Therapeutics Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $39.00.

Shareholding

Insiders
60.67%
Institutions
3.65%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC1.19%
Geode Capital Management, LLC0.35%
Longbow Finance SA0.33%
UBS Group AG0.31%
Vanguard Fiduciary Trust Co0.17%
BlackRock Inc0.12%
Steward Partners Investment Advisory, LLC0.04%
Paladin Partners, LLC0.02%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Mink Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.